Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 2959-2966

  Adams, Sylvia ^a   Gray, Robert J ^c   Demaria, Sandra ^a   Goldstein, Lori ^d   Perez, Edith A ^f   Shulman, Lawrence N ^c   Martino, Silvana ^g   Wang, Molin ^c   Jones, Vicky E ^h   Saphner, Thomas J ⁱ   Wolff, Antonio C ^j   Wood, William C ^k   Davidson, Nancy E ^e   Sledge, George W ^l   Sparano, Joseph A ^b   Badve, Sunil S ^l  

^a NEW YORK UNIVERSITY   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f MAYO CLINIC   (United States)

^g Angeles Clinic and Research Institute   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Saint Vincent Regional Cancer Center   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k EMORY UNIVERSITY   (United States)

^l INDIANA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CELL DENSITY; DISEASE FREE SURVIVAL; DISTANT RECURRENCE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907198355     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.55.0491     Document Type: Article

References (24)

1. Demaria S, Pilones KA, Adams S: Cross-talk of breast cancer cells with the immune system, in Gunduz M, Gunduz E (eds): Breast Cancer: Carcino-genesis, Cell Growth and Signalling Pathways. Rijeka, Croatia, InTech, 2011, pp 457-482
2. Aaltomaa S, Lipponen P, Eskelinen M., et al: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A:859-864, 1992
3. Denkert C, Loibl S, Noske A., et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
4. Loi S, Sirtaine N, Piette F., et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
5. West NR, Milne K, Truong P.T., et al: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126, 2011
6. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
7. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
8. Badve SS, Baehner FL, Gray R.P., et al: Estrogen and progesterone receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
9. Hammond ME, Hayes DF, Dowsett M, et al American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
10. Sparano JA, Wang M, Martino S., et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
11. Lin DY, Wei L: The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84:1074-1078, 1989
12. Barlow WE: Robust variance estimation for the case-cohort design. Biometrics 50:1064-1072, 1994
13. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2000
14. Arlen M, Flores L, Elguezbal A., et al: Nodal response in medullary carcinoma of the breast Am J Surg 131:263-266, 1976
15. Mahmoud SM, Paish EC, Powe D.G., et al Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955, 2011
16. Liu S, Lachapelle J, Leung S., et al: CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48, 2012
17. Adams S, Greeder L, Reich E., et al: Expression of cancer testis antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention? Cancer Immunol Immunother 60:999-1007, 2011
18. Curigliano G, Viale G, Ghioni M., et al: Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 22:98-103, 2011
19. Zhang L, Conejo-Garcia JR, Katsaros D., et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003
20. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
21. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
22. Zitvogel L, Tesniere A, Apetoh L., et al: Immu-nological aspects of anticancer chemotherapy [in French]. Bull Acad Natl Med 192:1469-1487, 2008; discussion 1487-1489
23. Demaria S, Formenti SC: Radiation as an immunological adjuvant: Current evidence on dose and fractionation. Front Oncol 2:153, 2012
24. Muenst S, Soysal SD, Gao F, et al: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139:667-676, 2013